Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026
[247 Pages Report] The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.
To know about the assumptions considered for the study, download the pdf brochure
Covid-19 Impact on the Leukapheresis Products and Leukopaks Market
In the optimistic scenario, it could be assumed that the pandemic has created a positive impact on the leukapheresis market. The ongoing clinical trials for COVID-19 vaccines could positively impact the leukapheresis products market, as the study of white blood cells is integral in supporting vaccine development. Moreover, some studies are also being carried out to understand the overall effect of COVID-19 on white blood cells. For instance, the NIH is conducting clinical trials that require leukapheresis to understand the effect of SARS-CoV-2 on lymphocytes. In the pessimistic scenario, it could be assumed that the COVID-19 pandemic has drastically lowered the demand for leukapheresis, especially for research purposes, and also reduced the demand for leukopaks. Therapeutic leukapheresis could be classified under essential procedures and, hence, would have resumed early post the stringent regulations, which were imposed in the first and second quarter of 2020 in many parts of the world. However, clinical trials were disrupted during this period and have not fully recovered in the post-lockdown period. This could affect the future demand for leukopaks in the pessimistic scenario.
Leukapheresis Products and Leukopaks Market Dynamics
Driver: Increasing incidence and prevalence of leukemia
Globally, the incidence of leukemia has risen significantly. According to the American Cancer Society, in 2021, there will be an estimated 61,090 new cases of leukemia in the US. It is also estimated that there will be an estimated 23,660 deaths in 2021 due to leukemia in the US. The incidence rate of leukemia in children has increased by 1% year-on-year from 2008 to 2020. It can be inferred that the rising incidence of hyperleukocytic leukemia will drive the number of therapeutic leukapheresis procedures conducted in the coming years and, thereby, support the growth of the leukapheresis market.
Restraint: High cost of therapeutic leukapheresis and leukopaks
The average price for apheresis devices ranges between USD 20,000 and USD 150,000. Hence, smaller blood banks and hospitals do not opt for this type of blood collection. Furthermore, qualified and skilled physicians/labor/nurses are also required for effective treatment and the collection/removal of WBCs using apheresis. All these factors make leukapheresis an expensive tool for short-term use. Similarly, the cost of leukapheresis at hospitals and cancer treatment centers is also very high as it incurs the additional cost of disposables—between USD 1,500 and USD 3,000 per patient. Therefore, the adoption of leukapheresis and leukopaks among small blood banks, research centers, and hospitals is very low, which, in turn, will restrain the growth of the leukapheresis market during the forecast period.
Opportunity: Leukapheresis for pediatric patients
Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side-effects and risks of conventional treatments such as chemotherapy for children. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed as well as emerging markets.
Challenge: Blood transfusion safety in developing countries
WBC transfusions have associated risks of transmitting infectious agents such as HIV, HBV, HCV, and malaria. Infection through the blood supply is a major issue, especially in developing countries such as India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during WBC transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the globe; moreover, the necessity of this step is more pronounced in developing countries where the burden of these diseases is higher. Thus, ensuring blood safety is a major challenge faced by blood and blood component suppliers and healthcare institutions in developing countries.
The leukapheresis devices segment is expected to grow at the highest CAGR, in the leukapheresis products market by type, in the forecast period
Leukapheresis devices are used for the separation of white blood cells (leukocytes) from whole blood. These instruments are also used to develop leukoreduced blood cell products such as leukoreduced plasma and leukoreduced RBCs. The growth of the leukapheresis devices market can largely be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel diseases. The increasing adoption of leukapheresis instruments by blood collection centers is another major factor supporting market growth.
The centrifugal devices segment holds the largest share in the leukapheresis devices segment, in the forecast period.
The centrifugal devices segment holds the largest share in the leukapheresis devices segment in the forecast period. The increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis, favorable reimbursement policies for therapeutic apheresis, and the increasing use of centrifugal apheresis for blood component donations by blood centers and hospitals are the major factors driving the growth of the centrifugal apheresis devices market. However, the higher cost of continuous apheresis in comparison with membrane separation is limiting the growth of this market to a certain extent.
Research applications is expected to grow at the highest CAGR in the leukapheresis products by application segment in the forecast period.
The research applications segment is expected to grow at the highest CAGR in the leukapheresis products, by application segment in the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies, the increasing and the increasing number of clinical trials using leukopaks as a starting raw material for the development of cell-based therapies.
In 2020, the blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market
The blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market in 2020. The high share of this segment can be attributed to the increasing number of blood donations, growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.
The mobilized leukopaks segment accounted for the largest share of the leukopaks market, by type, in the forecast period.
Based type, the mobilized leukopaks segment accounted for the largest share of the leukopaks market in the forecast period. The large share of this segment can be attributed to the increasing demand for low-granulocyte and low-hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.
The pancreatic cancer segment is growing at the highest CAGR in the leukopaks market, by application, in the forecast period.
Based on application, the pancreatic cancer segment is expected to grow at the highest CAGR in the forecast period. The high growth of this segment can be attributed to the high potential of CAR T Cell therapy in pancreatic cancer including its ability to be directed against novel epitopes and combined with other therapeutic regimens for the disease.
Asia Pacific is growing at the highest CAGR in the leukapheresis products and leukopaks market, by region in the forecast period.
The Asia Pacific is growing at the highest CAGR in the leukapheresis products and leukopaks market, by region in the forecast period. This high growth can be attributed to emerging markets in the Asia Pacific becoming prominent growth hotspots in the market due to factors such as the rising geriatric population, the growing prevalence of leukemia, improving healthcare infrastructure, increasing number of clinical trials in China, and increasing public and private investments for the development of CAR-T therapy.
Key Market Players
Key players in the leukapheresis products and leukopaks market: Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).
The prominent players in the global leukapheresis products and leukopaks market are
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size available for years |
2019-2026 |
|
Base Year Considered |
2020 |
|
Forecast period |
2021-2026 |
|
Forecast Unit |
Value (USD Million) |
|
Segments covered |
Leukapheresis Products Market: |
|
Geographies covered |
|
|
Companies Covered |
Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US). |
The research report categorizes the market into the following segments and subsegments:
Leukapheresis Products Market, By Type
- Leukapheresis Disposables
- Leukapheresis Devices
- Centrifugal Devices
- Membrane Separators
Leukapheresis Products Market, By Application
- Research Applications
- Therapeutic Applications
Leukapheresis Products Market, By End User
- Blood Component Providers & Blood Centers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospital & Transfusion Centers
Leukopaks Market, By Type
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
Leukopaks Market, By Application
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
Leukopaks Market, By Indication
- Acute Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Chronic Lymphocytic Lymphoma
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Other Indications
Leukopaks Market, By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
Leukaphersis Products and Leukopaks Market, by Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Rest of the World
Recent Developments:
- In September 2020, AllCells, LLC. (US) added cryopreserved leukopaks to its product portfolio to ensure access to high-quality primary cells without potential delivery delays.
- In June 2020, Haemonetics Corporation (US), announced an agreement to sell its Fajardo, Puerto Rico manufacturing operations of blood filters to GVS S.p.A. (Italy).
- In June 2020, StemExpress, LLC. (US) added frozen leukopaks, LE00 (2.5C, 5C, 10C), which are frozen after fresh blood collection and provide an enriched source of peripheral blood mononuclear cells for medical research.
- In January 2020, Fresenius Kabi (Germany) inaugurated the expansion of its transfusion and apheresis disposables plant in the Dominican Republic in Santa Domingo.
- In February 2019, Terumo BCT, Inc. (US) expanded its global footprint by opening its first regional office in sub-Saharan Africa, in Nairobi, Kenya.
Frequently Asked Questions (FAQ):
Which are the top industry players in the global leukapheresis products and leukopaks market?
The top market players in the global leukapheresis products and leukopaks market include Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Charles River Laboratories (US), AllCells, LLC (US), and StemExpress, LLC. (US).
Which are the segments that have been included in this report?
This report has the following main segments:
In the Leukapheresis Products Market:
- By Type
- By Application
- By End User
- By Region
In the Leukopaks Market:
- By Type
- By Indication
- By End User
- By Region
Which geographical region is dominating in the leukapheresis products and leukopaks market?
The global leukapheresis products and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2020, the North American region dominated the global leukapheresis products and leukopaks market. The prominence of the North American region in this market can be attributed to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR T-cell therapies, and the presence of leading pharma and biotech companies focusing on cell therapy research.
Which is the leading segment in the leukapheresis products market, by type?
The leukapheresis disposables commanded the largest market share the leukapheresis products market, by type, in 2020. The large share of this segment can be attributed to the attributed to the recurrent use of disposables during leukapheresis procedures and increasing adoption of leukapheresis products for the collection of leukopaks.
What is the current size of the global leukapheresis products and leukopaks market?
The global leukapheresis products market is projected to reach USD 91.6 million by 2026 from USD 61.2 million in 2021, at a CAGR of 8.4%. Meanwhile, global leukopaks market is projected to reach USD 662.3 million by 2026 from USD 115.0 million in 2021, at a CAGR of 41.9%. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 36)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS & LEUKOPAKS MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 8 REVENUE ANALYSIS OF THE TOP 4 COMPANIES: LEUKAPHERESIS MARKET (2020)
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS MARKET)
FIGURE 10 TOP-DOWN APPROACH
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
FIGURE 11 VOLUME ESTIMATION OF LEUKOPAKS MARKET
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET)
FIGURE 13 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS & LEUKOPAKS MARKET
2.8 COVID-19 HEALTH ASSESSMENT
2.9 COVID-19 ECONOMIC ASSESSMENT
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 15 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 16 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LEUKAPHERESIS AND LEUKOPAKS MARKET
3 EXECUTIVE SUMMARY (Page No. - 57)
FIGURE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 18 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 20 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 21 LEUKOPAKS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 22 LEUKOPAKS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 23 LEUKOPAKS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 24 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 25 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET
4 PREMIUM INSIGHTS (Page No. - 63)
4.1 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW
FIGURE 26 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
FIGURE 27 LEUKAPHERESIS DISPOSABLES COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2020
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
FIGURE 28 CHINA TO WITNESS THE HIGHEST GROWTH IN THE LEUKAPHERESIS PRODUCTS MARKET DURING THE FORECAST PERIOD
4.4 REGIONAL MIX: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 29 NORTH AMERICA DOMINATED THE MARKET IN 2020
4.5 LEUKOPAKS MARKET OVERVIEW
FIGURE 30 FAVORABLE GOVERNMENT SUPPORT AND RISING DEMAND FOR LEUKOPAKS IN RESEARCH APPLICATIONS TO DRIVE MARKET GROWTH
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
FIGURE 31 MOBILIZED LEUKOPAKS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN LEUKOPAKS MARKET IN 2020
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
FIGURE 32 CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.8 REGIONAL MIX: LEUKOPAKS MARKET
FIGURE 33 APAC MARKET TO WITNESS THE HIGHEST GROWTH
5 MARKET OVERVIEW (Page No. - 68)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 34 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing incidence and prevalence of leukemia
FIGURE 35 INCIDENCE AND MORTALITY RATES OF LEUKEMIA, BY REGION, 2020
5.2.1.2 Increasing number of blood donations
TABLE 3 COLLECTION OF WHOLE BLOOD UNITS, BY COUNTRY, 2015–2016 (MILLION UNITS)
5.2.1.3 Demand for leukopaks in clinical research
FIGURE 36 GROWTH IN THE NUMBER OF CAR-T CLINICAL TRIALS
5.2.2 MARKET RESTRAINTS
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
TABLE 4 COST OF LEUKOPAKS, BY TYPE
5.2.2.2 Stringent donor recruitment criteria
TABLE 5 DONOR SELECTION CRITERIA
TABLE 6 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
5.2.2.3 Dearth of skilled professionals and low adoption of therapeutic leukapheresis
5.2.2.4 Complications associated with therapeutic leukapheresis
5.2.2.5 Long procedural time for leukapheresis
5.2.2.6 High cost of cellular immunotherapies & lack of favorable reimbursement
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Leukapheresis for pediatric patients
5.2.3.2 Emerging economies and increasing investments from academic institutes, pharma-biotech companies, and leading players
5.2.4 MARKET CHALLENGES
5.2.4.1 Blood transfusion safety in developing countries
5.3 PORTER’S FIVE FORCES ANALYSIS
FIGURE 37 PORTER’S FIVE FORCES ANALYSIS (2020): LEUKAPHERESIS MARKET
TABLE 7 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 LEUKOPAKS: PRICING ANALYSIS
TABLE 8 ASP OF NON-MOBILIZED LEUKOPAKS
TABLE 9 ASP OF MOBILIZED LEUKOPAKS
TABLE 10 ASP OF MOBILIZED ISOLATED CELLS
5.5 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
5.5.1 NORTH AMERICA
5.5.1.1 US
5.5.1.2 Canada
5.5.2 EUROPE
5.5.3 ASIA PACIFIC
5.5.3.1 Japan
5.6 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
5.6.1 US
TABLE 11 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
5.6.2 EUROPE
5.6.3 JAPAN
5.6.4 CHINA
5.6.5 INDIA
5.7 VALUE CHAIN ANALYSIS
FIGURE 38 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
5.8 ECOSYSTEM MAP
TABLE 12 LEUKAPHERESIS MARKET: ECOSYSTEM
FIGURE 39 LEUKAPHERESIS MARKET: ECOSYSTEM MAP (2020)
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET
FIGURE 40 GLOBAL PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET, 2015–2020
5.9.2 TOP APPLICANTS (COMPANIES) FOR LEUKAPHERESIS PATENTS
FIGURE 41 TOP APPLICANT COMPANIES FOR LEUKAPHERESIS PATENTS, 2015–2020
5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR LEUKAPHERESIS MARKET PATENTS
FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKAPHERESIS PATENTS, 2015–2020
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY MARKETS FOR IMPORT AND EXPORT (TRADE ANALYSIS FOR APHERESIS-RELATED PRODUCTS & EQUIPMENT)
5.10.1.1 US
TABLE 13 US: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS
5.10.1.2 Russia
TABLE 14 RUSSIA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS
5.10.1.3 China
TABLE 15 CHINA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS
6 INDUSTRY INSIGHTS (Page No. - 92)
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 INCREASING NUMBER OF COLLABORATIONS AMONG PHARMA AND BIOTECH COMPANIES
TABLE 16 RECENT PHARMA-BIOTECH COLLABORATIONS FOR CAR-T THERAPY
6.2.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
6.2.3 USE OF LEUKAPHERESIS IN CLINICAL TRIALS TO DETERMINE CHANGES IN CELLULAR IMMUNE PROFILES IN COVID-19 INFECTIONS
7 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE (Page No. - 95)
7.1 INTRODUCTION
TABLE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 18 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.2 LEUKAPHERESIS DISPOSABLES
7.2.1 RECURRENT USAGE AND DEMAND FOR DISPOSABLES BOOSTING THE GROWTH OF THIS SEGMENT
TABLE 19 MANUFACTURERS OF LEUKOREDUCTION FILTERS
TABLE 20 MANUFACTURERS OF LEUKAPHERESIS COLUMNS & CELL SEPARATORS
TABLE 21 LEUKAPHERESIS DISPOSABLES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 LEUKAPHERESIS DEVICES
TABLE 22 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 23 LEUKAPHERESIS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1 CENTRIFUGAL DEVICES
7.3.1.1 Increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis to drive market growth
TABLE 24 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET
TABLE 25 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 MEMBRANE SEPARATORS
7.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood—a key factor limiting the adoption of these devices
TABLE 26 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET
TABLE 27 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION (Page No. - 104)
8.1 INTRODUCTION
TABLE 28 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 RESEARCH APPLICATIONS
8.2.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 29 LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 THERAPEUTIC APPLICATIONS
8.3.1 INCREASING ADOPTION OF LEUKAPHERESIS PROCEDURES AS A SUPPORTIVE TREATMENT IN LEUKEMIA TO DRIVE MARKET GROWTH
TABLE 30 LEUKAPHERESIS PRODUCTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD THOUSAND)
9 LEUKAPHERESIS PRODUCTS MARKET, BY END USER (Page No. - 108)
9.1 INTRODUCTION
TABLE 31 LEUKAPHERESIS PRODUCTS MARKET, BY END USER,2019–2026 (USD MILLION)
9.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
9.2.1 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS ARE THE LARGEST END USERS OF LEUKAPHERESIS PRODUCTS
TABLE 32 LEUKAPHERESIS PRODUCTS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES AND ACADEMIC & RESEARCH INSTITUTES WILL DRIVE MARKET GROWTH
TABLE 33 LEUKAPHERESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
TABLE 34 LEADING PHARMA-BIOTECH COMPANIES INVOLVED IN THE DEVELOPMENT OF CAR T-CELL TECHNOLOGIES
TABLE 35 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.5 HOSPITALS & TRANSFUSION CENTERS
9.5.1 GROWTH IN THE NUMBER OF HOSPITALS PERFORMING TRANSFUSION TO DRIVE MARKET GROWTH
TABLE 36 LEUKAPHERESIS PRODUCTS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
10 LEUKOPAKS MARKET, BY TYPE (Page No. - 115)
10.1 INTRODUCTION
TABLE 37 LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 38 LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
10.2 MOBILIZED LEUKOPAKS
10.2.1 MOBILIZED LEUKOPAKS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
TABLE 39 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
10.3 NON-MOBILIZED LEUKOPAKS
10.3.1 LOW COST AS COMPARED TO MOBILIZED LEUKOPAKS TO DRIVE MARKET GROWTH
TABLE 41 COMPARATIVE ANALYSIS OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS
TABLE 42 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
10.4 DISEASED LEUKOPAKS
10.4.1 RISING ADOPTION OF DISEASED LEUKOPAKS FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO DRIVE MARKET GROWTH
TABLE 44 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 DISEASED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
10.5 ISOLATED PBMCS
10.5.1 INCREASING FOCUS OF RESEARCHERS ON CELL-BASED THERAPIES TO DRIVE MARKET GROWTH
TABLE 46 ISOLATED PBMCS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 ISOLATED PBMCS MARKET, BY REGION, 2019–2026 (UNITS)
11 LEUKOPAKS MARKET, BY INDICATION (Page No. - 124)
11.1 LEUKOPAKS MARKET, BY INDICATION
FIGURE 43 GLOBAL NUMBER OF CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR CELLS
TABLE 48 LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 49 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION)
TABLE 50 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY REGION, 2019–2026 (USD MILLION)
TABLE 51 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 54 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY REGION, 2019–2026 (USD MILLION)
TABLE 55 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
12 LEUKOPAKS MARKET, BY END USER (Page No. - 129)
12.1 INTRODUCTION
TABLE 56 LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2 ACADEMIC & RESEARCH INSTITUTES
12.2.1 INCREASING NUMBER OF INDUSTRY-ACADEMIC PARTNERSHIPS FOR CONDUCTING RESEARCH ON CELL-BASED CANCER THERAPIES TO DRIVE MARKET GROWTH
TABLE 57 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT UTILIZING LEUKOPAKS AS STARTING MATERIAL TO DRIVE MARKET GROWTH
TABLE 58 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
12.4 CONTRACT RESEARCH ORGANIZATIONS
12.4.1 INCREASING SPONSORSHIP OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
TABLE 59 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
13 GEOGRAPHIC ANALYSIS (Page No. - 134)
13.1 INTRODUCTION
FIGURE 44 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 60 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2019–2026 (USD MILLION)
FIGURE 45 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 61 LEUKOPAKS MARKET, BY REGION, 2019–2026 (USD MILLION)
13.2 NORTH AMERICA
FIGURE 46 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 62 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.2.1 US
13.2.1.1 The presence of a large number of leading pharmaceutical and biotechnology companies to drive market growth in the US
FIGURE 47 NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS IN THE US, 2013–2020
TABLE 71 US: KEY MACROINDICATORS
TABLE 72 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 75 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 76 US: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 US: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.2.2 CANADA
13.2.2.1 Rising prevalence of blood cancer to stimulate market growth in Canada
TABLE 78 CANADA: KEY MACROINDICATORS
TABLE 79 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD THOUSAND)
TABLE 81 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
TABLE 82 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD THOUSAND)
TABLE 83 CANADA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 CANADA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.3 EUROPE
FIGURE 48 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 85 EUROPE: NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS, BY COUNTRY, 2015–2020
TABLE 86 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 90 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 91 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 94 EUROPE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.3.1 UK
13.3.1.1 Rising prevalence of target diseases to drive market growth in the UK
TABLE 95 UK: KEY MACROINDICATORS
TABLE 96 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
TABLE 99 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 100 UK: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 UK: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.3.2 GERMANY
13.3.2.1 Increasing research on cancer immunotherapies to drive market growth in Germany
TABLE 102 GERMANY: KEY MACROINDICATORS
TABLE 103 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
TABLE 106 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 107 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 GERMANY: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.3.3 SPAIN
13.3.3.1 Rising focus on the development of novel CAR T-cell therapies to drive market growth
TABLE 109 SPAIN: KEY MACROINDICATORS
TABLE 110 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
TABLE 113 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 114 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 SPAIN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.3.4 REST OF EUROPE
TABLE 116 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 ROE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 119 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 120 ROE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 ROE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.4 ASIA PACIFIC
FIGURE 49 APAC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 122 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 123 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 APAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 126 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 127 APAC: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 128 APAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 APAC: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 130 APAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.4.1 CHINA
13.4.1.1 Market in China to witness the highest growth during the forecast period
FIGURE 50 NUMBER OF CAR T-BASED CLINICAL TRIALS REGISTERED IN CHINA (2013–2020)
TABLE 131 CHINA: KEY MACROINDICATORS
TABLE 132 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 134 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 135 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 136 CHINA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 CHINA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.4.2 JAPAN
13.4.2.1 Several research activities in Japan are focusing on the development of leukopak-based cell therapies
TABLE 138 JAPAN: KEY MACROINDICATORS
TABLE 139 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 140 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
TABLE 142 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 143 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 JAPAN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.4.3 REST OF ASIA PACIFIC
TABLE 145 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 146 ROAPAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 148 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 149 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
13.5 REST OF THE WORLD
TABLE 151 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 ROW: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 154 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 155 ROW: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 156 ROW: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 157 ROW: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
14 COMPETITIVE LANDSCAPE (Page No. - 174)
14.1 INTRODUCTION
FIGURE 51 KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018–JANUARY 2021
FIGURE 52 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS DOMINATED THE LEUKAPHERESIS MARKET DURING 2018–2021
14.2 REVENUE SHARE ANALYSIS OF THE TOP 4 MARKET PLAYERS
FIGURE 53 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF THE TOP FOUR MARKET PLAYERS
14.3 PRODUCT FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE LEUKAPHERESIS AND LEUKOPAKS MARKETS
TABLE 158 COMPANY PRODUCT FOOTPRINT
TABLE 159 COMPANY INDUSTRY FOOTPRINT
TABLE 160 COMPANY APPLICATION FOOTPRINT
TABLE 161 COMPANY REGION FOOTPRINT
14.4 LEUKAPHERESIS MARKET SHARE (2020)
TABLE 162 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION
FIGURE 54 LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER (2020)
14.5 LEUKOPAKS MARKET SHARE (2020)
TABLE 163 LEUKOPAKS MARKET: DEGREE OF COMPETITION
FIGURE 55 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2020)
14.6 COMPETITIVE LEADERSHIP MAPPING (LEUKAPHERESIS MARKET)
14.7 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
FIGURE 56 LEUKAPHERESIS MARKET: COMPANY EVALUATION MATRIX, 2020
14.8 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (LEUKAPHERESIS MARKET) (2020)
14.8.1 PROGRESSIVE COMPANIES
14.8.2 DYNAMIC COMPANIES
14.8.3 STARTING BLOCKS
14.8.4 RESPONSIVE COMPANIES
FIGURE 57 LEUKAPHERESIS MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2020
14.9 COMPETITIVE LEADERSHIP MAPPING (LEUKOPAKS MARKET)
14.9.1 STARS
14.9.2 EMERGING LEADERS
14.9.3 PERVASIVE PLAYERS
14.9.4 PARTICIPANTS
FIGURE 58 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2020)
14.10 COMPETITIVE SITUATIONS AND TRENDS
TABLE 164 PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–JANUARY 2021)
TABLE 165 DEALS (JANUARY 2018–JANUARY 2021)
TABLE 166 OTHER DEVELOPMENTS (JANUARY 2018–JANUARY 2021)
15 COMPANY PROFILES (Page No. - 195)
15.1 KEY PLAYERS (LEUKAPHERESIS MARKET)
15.1.1 ASAHI KASEI CORPORATION
TABLE 167 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 59 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2020)
15.1.2 FRESENIUS SE & CO. KGAA
TABLE 168 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 60 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019)
FIGURE 61 FRESENIUS KABI: COMPANY SNAPSHOT (2019)
15.1.3 HAEMONETICS CORPORATION
TABLE 169 HAEMONETICS CORPORATION: BUSINESS OVERVIEW
FIGURE 62 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2018)
15.1.4 TERUMO BCT
TABLE 170 TERUMO BCT: BUSINESS OVERVIEW
FIGURE 63 TERUMO BCT: COMPANY SNAPSHOT (2020)
15.1.5 MACOPHARMA SA
TABLE 171 MACOPHARMA SA: BUSINESS OVERVIEW
15.1.6 MILTENYI BIOTEC
TABLE 172 MILTENYI BIOTEC: BUSINESS OVERVIEW
15.2 OTHER PLAYERS (LEUKAPHERESIS MARKET)
15.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
TABLE 173 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW
15.2.2 MEDICA SPA.
TABLE 174 MEDICA SPA: BUSINESS OVERVIEW
15.2.3 PURIBLOOD MEDICAL CO. LTD.
TABLE 175 PURIBLOOD MEDICAL CO. LTD.: BUSINESS OVERVIEW
15.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
TABLE 176 BEIJING ZKSK TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW
15.3 KEY PLAYERS (LEUKOPAKS MARKET)
15.3.1 ALLCELLS, LLC
TABLE 177 ALLCELLS, LLC: BUSINESS OVERVIEW
15.3.2 STEMEXPRESS, LLC
TABLE 178 STEMEXPRESS, LLC: BUSINESS OVERVIEW
15.3.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 179 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 64 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019)
FIGURE 65 HEMACARE CORPORATION: COMPANY SNAPSHOT (2018)
15.3.4 LONZA GROUP AG
TABLE 180 LONZA GROUP AG: BUSINESS OVERVIEW
FIGURE 66 LONZA GROUP AG: COMPANY SNAPSHOT (2019)
15.4 OTHER PLAYERS (LEUKOPAKS MARKET)
15.4.1 CALTAG MEDSYSTEMS LIMITED
TABLE 181 CALTAG MEDSYSTEMS LIMITED: BUSINESS OVERVIEW
15.4.2 ZENBIO, INC.
TABLE 182 ZENBIO, INC.: BUSINESS OVERVIEW
15.4.3 PRECISION FOR MEDICINE, INC.
TABLE 183 PRECISION FOR MEDICINE, INC.: BUSINESS OVERVIEW
15.4.4 BIOIVT
TABLE 184 BIOIVT: BUSINESS OVERVIEW
15.4.5 DISCOVERY LIFE SCIENCES
TABLE 185 DISCOVERY LIFE SCIENCES: BUSINESS OVERVIEW
15.4.6 INTELLIGENT TISSUE GROUP
16 APPENDIX (Page No. - 237)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 AVAILABLE CUSTOMIZATIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
Secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the leukaphereis and leukopaks market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The leukapheresis and leukopaks market comprises several stakeholders such as device manufacturers and distributors and regulatory organizations. The demand side of this market is characterized by hospitals & clinics, pharmaceutical and biotechnology companies, healthcare service providers (including hospitals and transfusion centers), blood component providers & blood centers, contract research organizations (CROs), and academic and research institutes.
Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents for leukopaks market is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, by application, by indication, by end user and by region).
Data Triangulation
After arriving at the market size, the total leukapheresis products and leukopaks market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, analyze, and forecast the size of the leukapheresis products and leukopaks market on the basis of product, application, indication, end user and region.
- To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, and Rest of the World.
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product launches, expansions, partnerships, agreements, collaborations, acquisitions and other developments in the market.
- To benchmark players within the leukapheresis products and leukopaks market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific leukapheresis products and leukopaks market into South Korea, New Zealand, and other countries
- Further breakdown of Rest of the World into Latin America and Middle East & Africa.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Leukapheresis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Leukapheresis Market